Clinical trials: Metastasis, open to volunteers
Urothelial Carcinoma, Biliary Tract Cancer
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
his single-center phase II clinical study enrolls patients with unresectable locally advanced or metastatic HER2-overexpressing biliary tract cancer or urothelial carcinoma who have failed standard treatment.
- Conditions
- Urothelial Carcinoma, Biliary Tract Cancer, HER2
- Trial name
- SHIELD (NCT07506057)
- Testing
- Trastuzumab+Serplulimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiujuan Qu
Breast Cancer, Metastatic Breast Cancer
PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer
This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, miRNAs, PTEN
- Trial name
- PTEN-miR-MBC (NCT07297134)
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Atlas University
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Castration-Resistant Prostatic Cancer, Metastasis
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06863272
- Testing
- Docetaxel, Ifinatamab Deruxtecan, Opevesostat
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 360 people
- Sponsor
- Merck Sharp & Dohme LLC
IO Resistant Squamous and Nonsquamous NSCLC
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally.
- Trial name
- MarsLight-11 (NCT07217301)
- Testing
- TAK-928, Control Arm
- Where
- 50 sites in United States, China and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Posttraumatic Headache
Hypersensitivity to Adrenomedullin in Post-Traumatic Headache
Adrenomedullin is a neuropeptide implicated in the pathogenesis of headache. This study investigates whether adrenomedullin induces headache with migraine-like features in people with persistent post-traumatic headache (PTH)…
- Trial name
- NCT07059546
- Testing
- Adrenomedullin
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Danish Headache Center
Cancer Pain
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer…
- Trial name
- NCT07008703
- Testing
- Injection of humanized nerve growth factor (NGF) antibody
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Gastric Cancer, Peritoneal Metastases
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent…
- Trial name
- NCT05722275
- Testing
- Peritoneal metastasis status ascertainment
- Where
- 13 sites in China, Italy
- Volunteers
- 400 people
- Sponsor
- Chinese Academy of Sciences
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors
FTT PET/CT in Pancreatic Neuroendocrine Tumors
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, [18F]FluorThanatrace ([18F]FTT).
- Trial name
- NCT07114939
- Testing
- [18F]FluorThanatrace
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Liver Cancer
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique.
- Trial name
- vGRID SBRT (NCT05727787)
- Testing
- Stereotactic Body Radiation Treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Kansas Medical Center
Head and Neck Cancer, Thyroid Cancer
New MRI Biomarkers in Head and Neck Cancers
Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt.
- Trial name
- NCT03483337
- Testing
- MRI examinations
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT03606967
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 30 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
CerebroSpinal Fluid (CSF) Leak
The Freiburg Registry on SpontanEous IntercrAnial Hypotension (SIH) & Post-duraL Puncture Headache (PDPH)
Spinal CSF leaks are considered as rare disease. They cause a variety of symptoms, mainly culminating in a chronic headache syndrome. Crucially, yet often disregarded, the disease holds the potential for cure.
- Trial name
- SEAL (NCT06711731)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- University Hospital Freiburg
Breast Cancer, Metastasis
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
- Trial name
- NCT05095207
- Testing
- Abemaciclib, Bicalutamide
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Persistent, Recurrent, or Metastatic Cervical Cancer
Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.
This is a phase II single-arm study of low-dose pembrolizumab (100mg, fixed-dose) plus chemotherapy in women aged 18 years or older with histologically confirmed persistent, recurrent, or metastatic cervical cancer who are…
- Trial name
- ACCESS-I (NCT06670911)
- Testing
- Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)
- Where
- Brazil
- Volunteers
- 44 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Advanced (Unresectable or Metastatic) Melanoma
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced…
- Trial name
- NCT07221734
- Testing
- MB11 (Proposed Nivolumab Biosimilar), EU-Opdivo®, US- sourced Opdivo®
- Where
- 86 sites in Bosnia and Herzegovina, Brazil and 11 more
- Volunteers
- 632 people
- Sponsor
- mAbxience Research S.L.
Head and Neck Neoplasms, Recurrent Disease
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell…
- Conditions
- Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
- Trial name
- NCT05260671
- Testing
- Penpulimab combined with cetuximab
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in…
- Conditions
- Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07262619
- Testing
- EIK1005, pembrolizumab (KEYTRUDA® )
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 160 people
- Sponsor
- Eikon Therapeutics
Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
The goal of this phase II/III randomized clinical trial is to evaluate the effect of adding rectal ozone therapy to the usual management of patients with paresthesia (numbness and/or tingling) due to chemotherapy-induced…
- Conditions
- Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, Tingling
- Trial name
- OzoParQT (NCT06706544)
- Testing
- Ozone therapy
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Bernardino Clavo, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.